Duke IGSP Research May Enable Oncologists To Use PGx to Prescribe Best Chemotherapy | GenomeWeb
A set of gene-expression profiles may be able to help oncologists better pick chemotherapies in about 80 percent of cases in three types of cancer, according to scientists at Duke University’s Institute for Genome Sciences and Policy.
The IGSP team’s approach differs from existing pharmacogenomic-based methods, such as Genomic Health’s Oncotype Dx, in that it is designed to enable doctors to pick from among seven drugs as opposed to identifying whether a single agent will be efficacious.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.